ASCL2 and neoplasm: Activating TLR4 may recede the suppressive inflammatory factors expression, including NF-κB, IL-1β, and IL-18 by the ASCL2 regulation, and induce the inflammatory injury to tumor cells, thereby being involved in the prognosis of this disease.